STOCK TITAN

Milestone Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Milestone Pharmaceuticals Inc. (Nasdaq: MIST) announced that CEO Joseph Oliveto will participate in a fireside chat at the H.C. Wainwright Global Investment Conference from May 23-26, 2022. The pre-recorded chat will be accessible starting May 24, 2022, at 7:00 am ET via their website. Milestone is focused on innovative cardiovascular medicines, with their lead product candidate, etripamil, in a Phase 3 clinical program for treating paroxysmal supraventricular tachycardia (PSVT) and in a Phase 2 trial for atrial fibrillation with rapid ventricular rate (AFib-RVR).

Positive
  • None.
Negative
  • None.

MONTREAL and CHARLOTTE, N.C., May 17, 2022 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto, President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright Global Investment Conference being held on May 23-26, 2022.

The pre-recorded fireside chat will become available on Tuesday, May 24, 2022 at 7:00am ET and can be accessed in the News & Events section of Milestone's website at www.milestonepharma.com. An archived replay of the presentation will be available on the same website for approximately 90 days following the presentation.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc. (Nasdaq: MIST), is a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines. Milestone's lead product candidate etripamil is currently in a Phase 3 clinical-stage program for the treatment of paroxysmal supraventricular tachycardia (PSVT) and in a Phase 2 proof-of-concept trial for the treatment of patients with atrial fibrillation with rapid ventricular rate (AFib-RVR). Milestone Pharmaceuticals operates in Canada and the United States. For more information, visit www.milestonepharma.com and follow Milestone on Twitter at @MilestonePharma.

Contact

David Pitts
Argot Partners
212-600-1902
david@argotpartners.com

(PRNewsfoto/Milestone Pharmaceuticals)

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/milestone-pharmaceuticals-to-present-at-the-hc-wainwright-global-investment-conference-301548550.html

SOURCE Milestone Pharmaceuticals, Inc.

FAQ

What is Milestone Pharmaceuticals' stock symbol?

The stock symbol for Milestone Pharmaceuticals is MIST.

When is Milestone Pharmaceuticals' fireside chat scheduled?

The fireside chat is scheduled for May 23-26, 2022.

How can I access the Milestone Pharmaceuticals fireside chat?

The fireside chat will be available on their website starting May 24, 2022, at 7:00 am ET.

What is the focus of Milestone Pharmaceuticals?

Milestone Pharmaceuticals focuses on developing innovative cardiovascular medicines.

What is the lead product candidate of Milestone Pharmaceuticals?

Milestone's lead product candidate is etripamil, aimed at treating PSVT and atrial fibrillation.

Milestone Pharmaceuticals Inc. Common Shares

NASDAQ:MIST

MIST Rankings

MIST Latest News

MIST Stock Data

78.84M
53.27M
0.69%
56.94%
0.84%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
MONTREAL